In recent years, novel drugs have been developed for the treatment of FSGS, including the B7-1 inhibitor abatacept [32], the latest generation of CD 20 monoclonal antibody (adalimumab) [33], mTOR inhibitor sirolimus [34], and others. Here, CD80 is linked to focal segmental glomerulosclerosis.